Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Tuong, S. Demura, E. Kogan (Russian Federation). Role of matrix metalloproteinases in progression of idiopathic pulmonary fibrosis. Eur Respir J 2010; 36: Suppl. 54, 4170

Member's Comments

No comment yet.

Related content which might interest you: Metalloproteinases in idiopathic pulmonary fibrosis Source: Eur Respir J 2011; 38: 1461-1467 Year: 2011 Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Matrix metalloproteinases in pulmonary fibrosis Source: Annual Congress 2013 –Regulation of lung inflammation and repair by proteolysis Year: 2013 Expression of elastolytic matrix metalloproteinases in bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 228s Year: 2002 Extracellular matrix profile of lung in idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Role of endothelin in lung fibrosis Source: Eur Respir Rev 2008; 17: 145-150 Year: 2008 Detrimental role for matrix metalloprotease-1 in the pathogenesis of pulmonary fibrosis Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis Year: 2017 Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012 Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007 Lysyl oxidases in idiopathic pulmonary fibrosis: A key participant in collagen I matrix remodelling Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis Source: Eur Respir J 2015; 46: 384-394 Year: 2015 Effect of the matrix metalloproteinase-9 on bone in chronic obstructive pulmonary disease Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002 Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 834-842 Year: 2005 The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006 MMP expression and abnormal lung permeability are important determinants of outcome in IPF Source: Eur Respir J 2009; 33: 77-84 Year: 2009 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 A role of matrix metalloproteinases and their inhibitors in the pathogenesis of fibrosis and angiogenesis in lung precancer processes Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010